BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37062647)

  • 1. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].
    Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J
    Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
    Xing KH; Connors JM; Lai A; Al-Mansour M; Sehn LH; Villa D; Klasa R; Shenkier T; Gascoyne RD; Skinnider B; Savage KJ
    Blood; 2014 Jun; 123(23):3567-73. PubMed ID: 24713929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
    Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
    Eichenauer DA; Engert A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Binkley MS; Advani RH
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):471-476. PubMed ID: 37076366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
    Unal A; Sari I; Deniz K; Ozkan M; Kontas O; Eser B; Cetin M
    Leuk Lymphoma; 2005 Nov; 46(11):1613-7. PubMed ID: 16236615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group.
    Mauz-Körholz C; Lange T; Hasenclever D; Burkhardt B; Feller AC; Dörffel W; Kluge R; Vordermark D; Körholz D
    Klin Padiatr; 2015 Nov; 227(6-7):314-21. PubMed ID: 26356319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variant histology of pediatric nodular lymphocyte-predominant Hodgkin lymphoma with IgD and CD30 expression.
    Ali N; Moussa E; Khorshed E; Zaghloul MS; Elnashar A; Abdalla A
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30647. PubMed ID: 37638819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group.
    Klekawka T; Balwierz W; Brozyna A; Chaber R; Dadela-Urbanek A; Koltan A; Kwasnicka J; Mitura-Lesiuk M; Muszynska-Roslan K; Przybyszewski B; Ruranska I; Smalisz K; Mizia-Malarz A; Stachowicz-Stencel T; Stolarska M; Wziatek A; Zielezinska K; Skoczen S
    Pediatr Hematol Oncol; 2021 Oct; 38(7):609-619. PubMed ID: 33734010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report.
    Shankar A; Hall GW; Gorde-Grosjean S; Hasenclever D; Leblanc T; Hayward J; Lambilliotte A; Daw S; Perel Y; McCarthy K; Lejars O; Coulomb A; Oberlin WO; Wallace WH; Landman-Parker J
    Eur J Cancer; 2012 Jul; 48(11):1700-6. PubMed ID: 22093944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
    Garciaz S; Harel S; Amorim S; Bouabdallah R; Thieblemont C; Brice P
    Br J Haematol; 2016 Nov; 175(4):735-737. PubMed ID: 26685097
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
    Eichenauer DA; Bühnen I; Baues C; Kobe C; Kaul H; Greil R; Moccia A; Zijlstra JM; Hertenstein B; Topp MS; Just M; von Tresckow B; Eich HT; Fuchs M; Dietlein M; Hartmann S; Engert A; Borchmann P
    Blood; 2023 Aug; 142(6):553-560. PubMed ID: 37257195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA; Varma G; Advani RH
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.